The combined company will still be called AbbVie, and is slated to be based in the United Kingdom, which will bring its tax rate down from 22 percent to 13 percent, according to the report.
Additionally, the proposed deal would increase Shire shareholders’ shares to approximately 25 percent of the new company, allowing the company to change its tax residence due to the acquisition, according to the report.
If completed, the acquisition would be one of the biggest mergers of the year, according to the report, exceeding Medtronic’s recent $43 billion acquisition of Covidien.
The deal is expected to close in the fourth quarter of 2013.
More Articles on Pharmaceuticals:
HHS Stands by 340B Drug Discount Policy
Another Court Sides With Pharmaceutical Companies, Dismisses Painkiller Cases
Duke University, Bristol-Myers Squibb Collaborate to Provide Clinical Trial Data Transparency
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
